Who Generates Higher Gross Profit? Gilead Sciences, Inc. or United Therapeutics Corporation

Gilead vs. United Therapeutics: A Decade of Profit Trends

__timestampGilead Sciences, Inc.United Therapeutics Corporation
Wednesday, January 1, 2014211020000001162636000
Thursday, January 1, 2015286330000001396725000
Friday, January 1, 2016261290000001526100000
Sunday, January 1, 2017217360000001619600000
Monday, January 1, 2018172740000001429100000
Tuesday, January 1, 2019177740000001331200000
Wednesday, January 1, 2020201170000001375200000
Friday, January 1, 2021207040000001563000000
Saturday, January 1, 2022216240000001789600000
Sunday, January 1, 2023206180000002070000000
Monday, January 1, 202478200000
Loading chart...

Unlocking the unknown

A Decade of Gross Profit: Gilead Sciences vs. United Therapeutics

In the competitive landscape of the pharmaceutical industry, Gilead Sciences, Inc. and United Therapeutics Corporation have showcased distinct trajectories in gross profit over the past decade. From 2014 to 2023, Gilead Sciences consistently outperformed United Therapeutics, with gross profits peaking in 2015 at approximately 28.6 billion, a staggering 20 times higher than United Therapeutics' 1.4 billion in the same year. However, United Therapeutics demonstrated a steady growth trend, culminating in a 78% increase in gross profit from 2014 to 2023. Meanwhile, Gilead's profits saw a decline of about 28% from their 2015 peak. This data highlights the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions can significantly impact financial outcomes. As we look to the future, these trends offer valuable insights into the evolving strategies of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025